ONKO 044
Alternative Names: IL-12v-ABD-Fc; ONKO-044Latest Information Update: 19 Mar 2025
At a glance
- Originator oNKo-innate
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Feb 2025 Preclinical trials in Cancer in USA (Parenteral) (Onko Innate pipeline, February 2025)